Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Listening...

Search Results

No Results

    Sorry, I don't understand. Please try again

    1. Home/
    2. News/
    3. Caring & giving/
    4. Ensuring babies have the first breath of life
    Our-Giving-Ensuring-Babies-Have-the-First-Breath-of-Life
    When Sun Yan’s daughter Wu Yuxuan was born, she could not breathe on her own until nurses performed life-giving resuscitation.

    Ensuring babies have the first breath of life

    When Sun Yan’s daughter Wu Yuxuan was born, she could not breathe on her own until nurses performed life-giving resuscitation.

    The Helping Babies Breathe (HBB) initiative trains health care workers in low-resource settings to intervene when newborns have birth asphyxia, the inability to breathe at birth. HBB is committed to increase the availability of skilled birth attendants at every birth. Nurses and midwives with HBB training have the skills to resuscitate over 90% of babies with birth asphyxia.

    In 2011, Johnson & Johnson made a $2 million 5-year investment to implement HBB in Malawi and Uganda in partnership with Save the Children. The partnership has trained more than 1000 skilled birth attendants, mostly midwives.

    HBB is an extension of over a decade of work with the Neonatal Resuscitation Program to address birth asphyxia, including a joint effort in China by Johnson & Johnson, the Chinese Ministry of Health and the American Academy of Pediatrics that has saved more than 190,000 babies. Since the program launched in 2004, newborn death caused by birth asphyxia has declined in China by more than 50% percent.

    To date, our programs address birth asphyxia in more than 12 countries including China, India, Indonesia, Vietnam, Nepal, Pakistan, Uganda, Malawi, Kenya, Ethiopia, Ghana and South Africa.

    More from Johnson & Johnson

    Striving for a cure for multiple myeloma: What HCPs need to know

    Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer.

    The future of immunology

    Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

    What is inflammation?

    Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.